期刊文献+

替加色罗大鼠体内药代动力学研究 被引量:4

Pharmacokinetic Studies of Tegaserod in Rats
下载PDF
导出
摘要 目的 建立大鼠血浆中替加色罗的HPLC测定法 ,以测定大鼠ig替加色罗后的血药浓度 ,并对其药代动力学进行评价。方法 血浆样品加入内标后用乙酸乙酯提取 ,进行HPLC分析 ,流动相为甲醇 乙腈 水 (6 0∶8∶32 ,含 0 8%冰醋酸 ,0 4 %三乙胺 ,v/v) ,流速为 1 0ml/min ,检测波长为 310nm。大鼠ig 5 0、10 0、2 0 0mg·kg-1替加色罗后 ,测定其血浆中替加色罗的浓度 ,计算主要药动学参数。结果 血浆中替加色罗在 2 0 0ng/ml~ 80 0 0ng/ml浓度范围内线性关系良好 ,血浆中替加色罗的最低检测限为 1 0ng/ml。大鼠ig 5 0、10 0、2 0 0mg·kg 1替加色罗后 ,估算的末端相半衰期分别为 0 86、1 0 9、1 0 8h ,3种剂量的半衰期相近 ,AUC与剂量间呈良好的线性关系 (r =0 9996 )。结论 本实验建立的分析方法灵敏、准确、简便。在5 0~ 2 0 0mg·kg 1剂量范围内 ,替加色罗在大鼠体内符合线性药物动力学特征 ,平均半衰期为 1 0 1h。 Aim To develop a HPLC assay for determination of tegaserod in rats plasma and to study the pharmacokinetics of tegaserod in rats.Method After spiked with the internal standard, plasma was extracted by ethyl acetate and separated by a C 18reversed-phase column.Result After ig administration of tegaserod with 3 dosages of 5.0,10.0 and 20.0 mg·kg -1to rats, the half-life of tegaserod in rats were estimated to be 0.86,1.09 and 1.08 h respectively, and the aresa under the concentration time curves correlated well with doses (r=0.9996).Conclusion The assay was proved to be sensitive, accruate and convenient. In the dosage rang of 5.0~20.0 mg·kg -1the pharmacokinetics of tegaserod in rats was linear and the average half-life of tegaserod in rat was 1.01 h.
出处 《江苏药学与临床研究》 2004年第4期3-5,共3页 Jiangsu Pharmacertical and Clinical Research
关键词 替加色罗 HPLC 药代动力学 Tegaserod HPLC Pharmacokinetics
  • 相关文献

参考文献2

  • 1[1]Appel S. First Pharmacokinetic-Pharmacodynamic study in humans with a selective 5-hydroxytryptaminer receptor agonist J Clin Pharmacol, 1997,37: 229-237.
  • 2[2]Li Ding, Xiao-dong Liu, Lin-min Li et al. Tissue Distribution and Excretion of Tegaserod in Rats. Asian Journal of Drug Metabolism and Pharmacokinetics, 2003,3 ( 4 ): 323 -326.

同被引文献14

  • 1司继刚,郭瑞臣,王本杰.马来酸替加色罗胶囊与其片剂的人体生物等效性[J].中国临床药学杂志,2006,15(2):96-99. 被引量:6
  • 2刘宁,苏静,黄建权,刘蕾,孙春华,史录文.高效液相色谱-串联质谱法测定人血浆中替加色罗的浓度[J].中国新药杂志,2007,16(8):644-647. 被引量:2
  • 3SILKE A,MARIE-ODILE L,ANETTE K,et al. Integrated modeling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist,following oral and intravenous administration [ J ]. Br J Clin Pharmacol, 1999,47 ( 5 ) :483 - 491.
  • 4SONU SS, HARSHVARDHAN P, KULDEEP S. Estimation of tegaserod in human plasma by high-performance liquid chromatography-tandem mass spectroscopy and its application to bioequivalence study [ J ]. Anal Chim Acta,2006,557 ( 1/2 ) :229 - 235.
  • 5国象食品药品监督管理局药品审评中心.药物临床信息参考[M].成都:四川科学技术出版社,2004:587—588.
  • 6Appel S, Kumle A, Hubert M, et al. First pharmacokineficpharmacodynamic study in humans with a selective hydroxytryptamine 4 receptor agonist [J]. J Clin Pharmacol, 1997, 37 (3) : 229-237.
  • 7Appel-Dingemanse S, Hirschberg Y, Osborne S, et al. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod[J]. Eur J Clin Pharmacol, 2001, 56(12): 889-891.
  • 8Swan SK, Zhou HH, Horowitz A, et al. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects [J]. J Clin Pharmacol, 2003, (43) : 359-364.
  • 9Appel S,Kumle A,Hubert M,et al.First pharmacokinetic-pharmacody-namic study in humans with a selective-hydroxytryptamine 4 receptor ago-nist[J].J Clin Pharmacol,1997,37(3):229.
  • 10Appel-Dingemanse S,Hirschberg Y,Osborne S,et al.Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod[J].Eur J Clin Pharmacol,2001,56(12):889.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部